SSR Mining Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? SSR Mining Inc. Common Stock trades at $31 (market cap $6.72B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: SSR Mining Inc. Common Stock is far larger — about 3.7× Vir Biotechnology Inc. Common Stock's market cap, and SSR Mining Inc. Common Stock pays a 0.09% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SSR Mining Inc. Common Stock for 1 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SSRM | VIR | |
|---|---|---|
Market Cap | $6.72B | $1.80B |
Volume | 3,758,896 | 1,782,836 |
Sector | Basic Materials | Health |
52-Week High | $39.21 | $11.78 |
52-Week Low | $19.48 | $5.12 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.89B | $1.36B |
Dividend Yield | 0.09% | — |
Signals from Pluang's Aura AI — not financial advice
SSR Mining (SSRM) trades at $33.09, down 6.63% amid recent volatility, yet maintains strong fundamentals with a P/E of 12.44 and net income margin of 12.3%. The company recently announced the $464 million acquisition of Roxmore Resources, which could add 170,000 ounces of annual gold production. Technical indicators show a bullish trend with support at $34-$35, while earnings have beaten expectations in two of the last three quarters.
The outlook remains positive with a consensus price target of $42.67 (29% upside), driven by strategic acquisitions and Americas-focused growth. Risks include execution of the Roxmore integration and gold price sensitivity. Analysts are bullish (73% buy ratings), citing the company's debt-free balance sheet and $1.8 billion cash position.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
SSR Mining operates precious-metals mines in the United States, Canada, and Argentina. It produces gold doré and concentrates containing copper, silver, lead, and zinc.
Read more on SSRM →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →